PMseq™ Pathogen Metagenomic Sequencing is based on metagenomics, which allows for the simultaneous detection of major microorganisms in a sample using next-generation sequencing without the need for prior knowledge of their identities. PMseq™ can detect more than 36,000 types of pathogens, including bacteria, fungi, viruses, parasites, etc., as well as representative drug resistance and virulence genes without bias. By using PMseq™, the positive rate of pathogen diagnosis can be significantly increased, guiding the clinical targeted use of antibiotics and assisting in the precise diagnosis and treatment of infections.

Applicable Population

• Complicated or unexplained infectious patients
• Severe Infectious Patients
• Immunocompromised Patients

Detection Scope

PMseq™ Pathogen Metagenomic Sequencing – Detects over 36,000 pathogens and their representative resistance and virulence genes in a single test, and also supports analysis of human chromosomal copy number variations (CNV).

• Bacteria: 16,343 (Including 226 Mycobacteria and 179 Mycoplasma/Chlamydia/Rickettsia)
• Fungi: 2,431
• Viruses: 16,679 (Including 11,545 DNA viruses, 5,134 RNA viruses)
• Parasites: 718
• Drug resistant Gene: 33 (Detects 67 types of antibiotic-resistant bacteria, including genes/sites such as CTX-M, KPC, OXA, MecA, NDM, and 23S rRNA.)
• Virulence Genes: 281 (Including rmpA, rmpA2, iutA, hly, ctxA/ctxB, etc.)

Sample Types

1. High Data Volume

High-throughput sequencing technology boosts data output, ensuring ultra-sensitive pathogen detection and robust support for precise diagnosis of complex infections.

2. Comprehensive Testing

One-time detection of 36,000 pathogens, including drug-resistant and virulence genes (e.g., Mycobacterium tuberculosis resistance mutations), for full-spectrum pathogen analysis in complex infections.

3. Precision Processing

Targeted sample pretreatment and optimized workflows enhance testing sensitivity, delivering accurate, reliable results for clinical decisions.

4. Clinical-level Database

Powered by a clinical-grade database and intelligent algorithms, ensuring precise report outcomes to guide diagnosis and treatment of complex infections.

5. Fully Qualified

End-to-end process—from nucleic acid extraction to analysis software—holds clinical certifications, guaranteeing quality, authority, and credibility of results.

6. Reliable Performance

Standardized quality management ensures stable, consistent testing. Years of passing NHC’s mNGS external quality assessments validate the accuracy and reliability.

Delivery Location: Hong Kong - Shenzhen

Turnaround Time (TAT) *: ≤7 working days

Note*: TAT is calculated from the Hong Kong center sample acceptance to the Shenzhen laboratory report release.

The solution includes all modules of instruments, reagents, analysis software and tech-transfer service which can realize the whole process of sample processing, sequencing and reporting locally.

• User-friendly control

Independently developed desktop sequencer and automatic processing system.

• Accurate detection

Patented DNB nanoball (DNB) library construction technology and Combinatorial Probe-Anchor Synthesis sequencing technology.

• Flexible throughput

Metagenomic sequencing of 1-48 samples can be performed at a time depending on different sequencing platforms.

• Comprehensive and intelligent

Comprehensive pathogen genome reference database and intelligent reporting system that fully meet clinical needs.

• Convenient and fast

For localized operation, TAT time from sample processing to obtaining report is within 24 hours.